Fluidigm Advanta Immuno-Oncology Gene Expression Assay

Fluidigm has launched the Advanta Immuno-Oncology Gene Expression Assay, a research-use-only qPCR assay that enables interrogation of tumor immunobiology using Fluidigm's microfluidic technology. Designed for use with the Biomark HD system, the assay detects 170 gene expression markers involved in checkpoint therapeutic response from FFPE and fresh frozen tumor samples. The assay can analyze biomarkers across defined T cell subsets, immune regulation, immune cell fate, cytokines, chemokines, and more, and can enable translational researchers to accelerate the development of checkpoint immunotherapies and to identify predictive biomarker signatures for therapeutic response.

Fluidigm said that the product is available as a two-panel set. The first panel includes 91 key markers of tumor immune response that were previously shown in a multicenter international clinical trial to inform tumor progression and checkpoint therapeutic response. The second panel includes 74 additional immuno-oncology markers and 17 open assay inlets for additional customization. Both panels contain the same five reference genes and can be purchased and used together or separately.